Sangamo Adds To Its Own Gene Therapy Technology With Ceregene Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech will bolster its own internal programs, as well as gain a potentially lucrative mid-stage asset through the acquisition, with no effect on its own balance sheet.
You may also be interested in...
Sangamo On A Roll, Clarifies Timelines And Catalysts, Takes On CRISPR
Sangamo used 2013 to progress its pipeline, to raise money and to acquire a company. The momentum carried into the first quarter of 2014 with the Biogen partnership and a jump in share price that suggested that investors finally may have bought into the gene therapy company’s unique story.
Third Quarter Earnings Briefs: Lilly, Bristol, Shire, Biomarin, Alexion
Lilly lowers expectations for Cymbalta; Celgene’s Abraxane continues with strong sales; Bristol touts the potential of Eliquis and Bydureon, despite slow sales; Ornskov discusses One Shire plan; BioMarin readies fifth compound for the clinic, and more.
Deals Of The Week: How Do 2013 Biotech Deal Stats Stack Up After Amgen/Onyx?
A busy summer of biotech acquisitions, including the pricey buyouts of Onyx by Amgen and Elan by Perrigo, has lifted the number of U.S. public biotech acquisitions so far in 2013 – and increased the average value of those deals. In other deal news, Endo plans to acquire Boca Pharmacal, Medimmune will buy out Amplimmune, and Eli Lilly signed a diabetes research deal with Zealand Pharma.